Seminal vesicles

The Paul G. Allen Family Foundation awards $10.5 million to new Allen Distinguished Investigators

Retrieved on: 
Tuesday, November 21, 2023
Medicine, Brain, Genetics, Research, Behavior, Reproduction, Hormone, Immune system, Inflammation, Testosterone, Allen Institute, EVS, Immunity, Microscopy, B cell, Disease, Protein, Learning, Mortality, Cardiovascular disease, Glossary of biology, Extracellular vesicle, Lipoprotein, Male, Neuron, Map, Animal, Machine learning, Health, COVID-19, Seminal vesicles, Ageing, Administration, Infection, Estradiol, Mammal, Neuroendocrinology, EV, DSM-IV codes, Skin, Female, Innovation, Cell, Biology, Traffic barrier, Pharmaceutical industry, Vaccine, Fireworks, Birth control, Science

18 researchers will develop technologies, design approaches and uncover insights into fundamental areas of human biology

Key Points: 
  • 18 researchers will develop technologies, design approaches and uncover insights into fundamental areas of human biology
    The Paul G. Allen Family Foundation will award $1.5 million to seven research projects which 18 researchers will lead.
  • "Our two newest cohorts of Allen Distinguished Investigators are using innovative technologies and unprecedented ambition to pioneer new frontiers in the fields of sex hormones and extracellular vesicles.
  • said Kathy Richmond , Ph.D., M.B.A., Executive Vice President and Director of the Frontiers Group and the Office of Science and Innovation at the Allen Institute.
  • Including the new awards, a total of 130 Allen Distinguished Investigators have been appointed during the past 12 years.

Kinetic River Corp. Signs Representation Agreements With Six Sales Organizations

Retrieved on: 
Tuesday, November 7, 2023
EV, NTA, Nanoparticle tracking analysis, Nanoparticle, PPM, Organization, EHV, NS, EVS, Government, LBT, NBS, Orders, decorations, and medals of the Canadian provinces, Flow cytometry, Seminal vesicles

MOUNTAIN VIEW, Calif., Nov. 7, 2023 /PRNewswire/ -- Kinetic River Corp., a leader in advanced flow cytometry instrumentation, announced today that it has signed agreements for representation of its Delaware Flow NanoCytometer™ with six sales organizations across North America. The six organizations are Precision Particle Measurements, Inc. (PPM; for Delaware, Maryland, Pennsylvania and West Virginia); New England Analytical Instruments (NEAI; for Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York City, Rhode Island, and Vermont); LB Technologies (LBT; for Alabama, Florida, Georgia, upstate New York, North Carolina, South Carolina, and Virginia); NanoBio Systems, Inc. (NBS; for Illinois, Indiana, Iowa, Kansas, Kentucky, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin); Nanostars, LLC (NS; for Arkansas, Louisiana, Mississippi, Oklahoma, Tennessee, and Texas) and E=hv (EHV; for Alaska, Arizona, California, Colorado, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming). In addition, NanoBio Systems will be responsible for the Canadian Provinces of Alberta, Manitoba, Ontario, and Saskatchewan.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 7, 2023 /PRNewswire/ -- Kinetic River Corp., a leader in advanced flow cytometry instrumentation, announced today that it has signed agreements for representation of its Delaware Flow NanoCytometer™ with six sales organizations across North America.
  • Kinetic River develops and manufactures high-performance flow cytometers and other optical analyzers.
  • They have great depth of expertise selling exactly the kind of instrumentation we specialize in," said Giacomo Vacca, Ph.D., president and CEO of Kinetic River.
  • "Kinetic River has developed the perfect complement to Particle Metrix's Nanoparticle Tracking Analysis (NTA) capabilities," said Gary Linz, CEO of Precision Particle Measurements.

STRM.BIO to Present Preclinical Data on a Novel Bone Marrow/HSC-Targeted, Megakaryocyte-Derived Extracellular Vesicle Delivery Platform for In Vivo Gene Therapy at ASH 2023

Retrieved on: 
Thursday, November 2, 2023
ASH, Stem cell, Hematology, VC, Bone marrow, EVS, Seminal vesicles, Therapy, Society, Vaccine

BOSTON, Nov. 2, 2023 /PRNewswire/ -- STRM.BIO , a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new therapeutics for rare blood diseases, today announced that it will present preclinical data on their novel delivery platform for in vivo gene therapy that uses megakaryocyte-derived EVs to target hematopoietic stem cells in the bone marrow at the 65th American Society of Hematology (ASH) Annual Meeting being held in San Diego, California, December 9 – 12, 2023.

Key Points: 
  • BOSTON, Nov. 2, 2023 /PRNewswire/ -- STRM.BIO , a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new therapeutics for rare blood diseases, today announced that it will present preclinical data on their novel delivery platform for in vivo gene therapy that uses megakaryocyte-derived EVs to target hematopoietic stem cells in the bone marrow at the 65th American Society of Hematology (ASH) Annual Meeting being held in San Diego, California, December 9 – 12, 2023.
  • The data to be presented demonstrates that megakaryocyte-derived EVs:
    Details of the poster presentation are as follows:

STRM.BIO CEO Jonathan Thon, Ph.D. to Deliver the 2023 R. D. Zeigler Innovation Research Lecture Sponsored by the Versiti Blood Research Institute

Retrieved on: 
Thursday, October 19, 2023
Lecture, Hematology, VC, EVS, Seminal vesicles, Research, Therapy, Medical device

BOSTON, Oct. 19, 2023 /PRNewswire/ -- STRM.BIO , a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new therapeutics for rare blood diseases, today announced that CEO Jonathan Thon, Ph.D. is the featured speaker at the 5th annual R. D. Zeigler Innovation Research Lecture Sponsored by the Versiti Blood Research Institute.

Key Points: 
  • BOSTON, Oct. 19, 2023 /PRNewswire/ -- STRM.BIO , a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new therapeutics for rare blood diseases, today announced that CEO Jonathan Thon, Ph.D. is the featured speaker at the 5th annual R. D. Zeigler Innovation Research Lecture Sponsored by the Versiti Blood Research Institute.
  • The lecture will take place on Monday, October 23rd at 3pm CT.
  • Versiti is a nonprofit blood health organization.
  • Ziegler Innovation Lecture, endowed by Peter and Joan Ziegler, was created to promote innovation at Versiti by sponsoring speakers to share their perspectives on the advancement of research and clinical care.

NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum

Retrieved on: 
Thursday, October 5, 2023
Food, SCI, 3D, Seminal vesicles, EVS, PTEN, NRX, FSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Small RNA, CNS, Patient, Exosome, Pharmaceutical industry

Dr. Shaltiel’s presentation will focus on the transformative potential of extracellular vesicles loaded with PTEN-siRNA (ExoPTEN) and the key challenges in translating this innovative therapy to the clinical stage, following the positive response from the Company’s pre-IND meeting with the U.S. Food and Drug Administration that was announced recently.

Key Points: 
  • Dr. Shaltiel’s presentation will focus on the transformative potential of extracellular vesicles loaded with PTEN-siRNA (ExoPTEN) and the key challenges in translating this innovative therapy to the clinical stage, following the positive response from the Company’s pre-IND meeting with the U.S. Food and Drug Administration that was announced recently.
  • During the presentation, Dr. Shaltiel will address critical aspects of NurExone’s ExoTherapy (exosome-based therapy), including the loading efficiency of extracellular vesicles (EVs) with siRNA and the large-scale production of EVs utilizing a revolutionary 3D bioprocess concept.
  • These advancements represent a step forward in the field of recovery from spinal cord injury and hold promise for patients globally.
  • The presentation will take place at the Extracellular Vesicles Forum in Cambridge, UK, on October 10th and 11th at the session titled “Exosome Based Therapies and Regenerative Medicine.” Dr. Shaltiel will be available for one-on-one meetings during the conference.

Global EV-Based Liquid Biopsy Market Research Analysis and Forecast Report 2023-2032: Opportunities Looming with New Approved Products & Development of New EV-Based Biomarkers - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 10, 2023
Health, Oncology, Diagnosis, Center for Urban and Regional Analysis, Workflow, Biomarker, Thermo Fisher Scientific, Seminal vesicles, QIAGEN, EVS, EV, Cancer, Collection, Growth, Region, Competitive landscape, Research, Pharmaceutical industry, Medical imaging, Video game

In 2022, the North America region dominated the global EV-based liquid biopsy market, and it is expected to hold its dominance throughout the forecast period 2023-2032.

Key Points: 
  • In 2022, the North America region dominated the global EV-based liquid biopsy market, and it is expected to hold its dominance throughout the forecast period 2023-2032.
  • The global EV-based liquid biopsy market has experienced substantial growth driven by technological advancements, rising demand for non-invasive diagnostics, and the global increase in cancer prevalence.
  • The global EV-based liquid biopsy market is in progressing phase, which can be attributed to the increase in academic research and approval of products in the market.
  • Based on end user, academic and research segment accounted for the largest share of the global EV-based liquid biopsy market in FY2022.

Hackensack Meridian Health Research Institute Creates First Spin-off Company, EValuate Diagnostics

Retrieved on: 
Wednesday, October 4, 2023
Hackensack Meridian Health, CDI, Commercialization, Evaluation, Neoplasm, Infection, Cancer, Hackensack Meridian School of Medicine, Breast, Medicine, Research, Biomarker, RNA, Lung, Science, EVS, Bear, Discovery, Seminal vesicles, Prostate Cancer Foundation, Patient, Physician, Blood, FACS, Den, Exosome, Health, Laboratory, Disease, Medical imaging, Pharmaceutical industry, Innovation, Urology

EDISON, N.J., Oct. 4, 2023 /PRNewswire/ -- The Hackensack Meridian Health Research Institute and its Office of Innovation and Commercialization have taken the step of establishing the first spin-off company based on science developed within the Hackensack Meridian Health network. The company aims to make tests detecting cancer and other diseases earlier than ever before.

Key Points: 
  • "This is a remarkable breakthrough for our health network, and for patients of the future," said Robert C. Garrett, FACHE, chief executive officer of Hackensack Meridian Health.
  • "We are taking the science produced by our terrific minds at the Hackensack Meridian Health Research Institute, and then moving it to the market so it can benefit all.
  • "This is a new milestone for innovation at Hackensack Meridian Health," said Ihor Sawczuk, M.D., FACS, Hackensack Meridian Health's president of Academics, Research and Innovation, founding chair of the Hackensack Meridian Health Research Institute, and also associate dean of Clinical Integration and professor and chair emeritus of Urology at the Hackensack Meridian School of Medicine.
  • The Office of Innovation and Commercialization launched in 2022 and promises to support innovations and discoveries across Hackensack Meridian Health.

ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues

Retrieved on: 
Wednesday, October 4, 2023
Heart, ASC, Tissue, MEFV, University, Microbiology, Inflammasome, Leonard M. Miller School of Medicine, AIM2, Serum, Associate professor, Neurosurgery, Traumatic brain injury, Bacterial conjugation, Brain, TBI, Inflammation, Research, CNS, EVS, Super Meat Boy, Seminal vesicles, Journal, Patient, Translational research, Invention, Mouse, Paper, Immunology, Therapy, Injury, Physiology, Pharmaceutical industry, Vaccine, Medication, Biophysics, Medicine

Marks the third publication in 2023 supporting the potential need to attenuate the spread of inflammation to surrounding tissues to minimize the potential for co-morbidities in certain diseases.

Key Points: 
  • Marks the third publication in 2023 supporting the potential need to attenuate the spread of inflammation to surrounding tissues to minimize the potential for co-morbidities in certain diseases.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100 to inhibit multiple types of inflammasomes and their associated ASC specks that trigger damaging inflammation and its spread to surrounding tissues.
  • Data indicate that pyrin inflammasome-mediated inflammation induced by TBI contributes to cardiovascular co-morbidities through systemic release of proinflammatory mediators that activate AIM2 inflammasomes in the heart leading to damaging inflammation.
  • “A heightened systemic inflammatory response is often induced after TBI, but the underlying pathomechanisms that contribute to co-morbidities remain poorly understood.

CHOP Researchers Improve Fitness of Cells Used in Cell Transplants

Retrieved on: 
Wednesday, September 27, 2023
Hematopoietic stem cell transplantation, University, Blood, CHOP, HLA, Culture, Genomics, Gene editing, Proteomics, Research, Cell, T32, Child, Doctor of Philosophy, HSCT, EVS, Transplant, Seminal vesicles, Flow cytometry, MD, Patient, Risk, DOI, Sickle cell disease, Mouse, Hospital, NIH, Hematopathology, Safety, Children's Hospital of Philadelphia, Vaccine, EV, HSPC

PHILADELPHIA, Sept. 27, 2023 /PRNewswire/ -- A readily available, inexpensive small molecule drug can improve the fitness of hematopoietic stem and progenitor cells (HSPCs) that are modified outside of the body, potentially improving the success of procedures like ex vivo gene therapy, according to a new study by researchers at Children's Hospital of Philadelphia (CHOP). The study, published in the journal Blood, showed that targeting components in the cells called extracellular vesicles (EVs) relieves the stress on cells when outside of the body, improving their performance when they are transplanted back inside.

Key Points: 
  • Hematopoietic stem cell transplantation (HSCT) involves the transfer of HSPCs from a donor to patients with both benign and malignant diseases.
  • However, maintaining the fitness of these cells outside of the body poses a challenge, and any loss of fitness introduces the risk that the cells will not properly restore the blood and immune cell system in patients.
  • One process that we now learn contributes to cell equilibrium is the secretion of EVs, which are important for delivering messages from cell to cell and maintaining proper cell function.
  • "Neutral sphingomyelinase blockade enhances hematopoietic stem cell fitness through an integrated stress response," Blood, online Sept. 12, 2023, DOI: 10.1182/blood.2023022147

STRM.BIO to Present at 2023 Cell & Gene Meeting on the Mesa

Retrieved on: 
Thursday, September 21, 2023
Therapy, Safety, Gene editing, Bone marrow, Regenerative medicine, EVS, Health, Seminal vesicles, Tissue engineering, Mesa, Cell, Liver, VC, Vaccine

BOSTON, Sept. 21, 2023 /PRNewswire/ -- STRM.BIO announced today that Dr. Jonathan Thon, Founder and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 10-12, 2023 in Carlsbad, California and livestreamed globally.

Key Points: 
  • BOSTON, Sept. 21, 2023 /PRNewswire/ -- STRM.BIO announced today that Dr. Jonathan Thon, Founder and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 10-12, 2023 in Carlsbad, California and livestreamed globally.
  • Safety and tolerability data in large animal models show amenability of the platform to repeat dosing.
  • Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa includes more than 120 company presentations by leading public and private companies in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies.
  • Complimentary attendance at this event is available for credentialed investors and members of the media only.